CEM 2016 announces Conference Programme


The organisers of CEM 2016, the international emissions monitoring event, have published details of the conference that will run over three days in Lisbon from 18th to 20th May. Featuring speakers from 13 countries there will be 48 presentations within seven main themes:


• Regulation Standards and Quality • Predictive Emission Monitoring • Innovative Measurement Technology • Fine Particulate Monitoring • Mercury and other Trace Metals • Fugitive Emissions • Industrial Case Studies


Increased Interactivity at Laborama Expo


Visitors to Laborama Expo, 17th and 18th March, Brussels Kart Expo, will find an increased level of participation to broaden knowledge of current enabling technology, services and good laboratory practice.


At the moment around a 100 companies have confirmed their presence as an exhibitor at this professional fair, with a readiness to present their latest innovations to a specialised public of end-users. Each year, 2000 visitors from all over Belgium come to visit this increasingly popular event.


The main theme for 2016 is safety in the lab and visitors will be able to take opportunities to participate in an educational tour that takes them by several exhibitors. On each booth of the tour the visitor receives a question and a successful participation results in a certificate of participation. Visitors can also attend interactive seminar sessions regarding safety in the lab.


Laborama Expo 2016 will also boast a fully equipped clean room. This is also a project for which multiple exhibitors will work together. Visitors will be informed about the presented equipment and can pose questions to the onsite specialists.


Visitors can register via the website expo.laborama.be. Here you can also find the entire exhibitor catalogue, floorplan, and other practical information on Laborama Expo 2016.


37588pr@reply-direct.com


The Conference presentations will address a wide range of testing and monitoring issues covering the latest international regulations, standards, methods and technologies in applications including laboratory analysis of land and sea-based emissions of fuel stocks, waste, construction and chemical industries.


CEM 2016 organiser Marcus Pattison believes that the CEM 2016 Conference is particularly well timed. “The emissions reduction targets agreed by 195 nations at COP21 in Paris will place a growing emphasis on the accuracy and reliability of monitoring at a time when, thanks to Volkswagen, public understanding of air pollution issues has never been greater. The automotive industry is keen to highlight the significance of industrial emissions, so it is vital that industry continues to provide ‘real-world’ data that can be trusted.


“According to the World Health Organisation, in 2012 air pollution was responsible for 3.7 million deaths, representing 6.7% of total deaths. This pollution caused about 16% of


lung cancer deaths, 11% of pulmonary disease deaths and more than 20% of deaths from heart disease and strokes. Air pollution is the single largest environmental health risk in Europe; responsible for more than 430,000 premature deaths every year.”


CEM 2016 is the 12th in a series of international events focusing on emissions monitoring. In addition to the CEM Conference, there will also be a Poster Display of research projects and an Exhibition featuring over 50 of the world’s leading monitoring instrumentation and service providers.


CEM 2016 abstracts for all of the presentations are available at www.cem.uk.com/conference-programme/ and earlybird registration will be available until 15th April.


37583pr@reply-direct.com


Emerging Trends in Quantitative Proteomics 2016


Registration for ProteoMMX 4.0 an International Conference on Quantitative Proteomics, which will be held on 5th - 7th April in Chester, UK has now opened.


In an ever-changing field like quantitative proteomics, new developments occur every day. Staying current with the latest trends and advancements is no easy task. ProteoMMX 4.0 is an open and friendly forum for postgraduate students, postdoctoral fellows, and established scientists to tap into each other’s passion and expertise for quantitative proteomics in an effort to advance the state of the science.


Registrants will hear from some of the most learned practitioners of proteomics including:


Benjamin Rupprecht, Technische Universität München Ben Collins, ETH, Zurich Mark Biggin, Lawrence Berkeley National Laboratory Clare Mills, University of Manchester Don Jones, University of Leicester Markus Schirle, Novartis Institutes for Biomedical Research Andrew Dowsey, University of Liverpool


Session topics will include: Spatio Temporal Proteomics, Clinical/Translational Proteomic Informatics and Data Handling, Integrative TransOmics Strategies, Dynamics of Proteins and Their Modification.


Further information: http://www.proteommx.org/ 37587pr@reply-direct.com


Alexy Neszivhskii, University of Michigan Matthias Trost, University of Dundee Sabine Bahn, University of Cambridge Erik Soderblom, Duke University Martin Miller, University of Cambridge


Enhancing Translation of Phenotypic Biology to Novel Therapeutics


The Universities of Dundee, Oxford and Edinburgh have announced the formation of the Phenotypic Discovery Initiative (PDi) with Janssen Pharmaceutica NV the first industry partner joining the initiative. Through the PDi, partners aim to build robust, disease-relevant phenotypic assays with a focus on human-derived systems with the aim of identifying new drug targets and hit molecules. Promising candidates will be followed up for their mechanism of action in the cell in order to further their development into drugs.


By including the complex characteristics of cell and tissues in healthy and diseased samples, high-throughput phenotypic screening offers the possibility of discovering drugs that act through new pathways, as well as novel targets with unique mechanisms. The expectation is that compounds discovered in this manner will have a higher probability of clinical success.


The PDi will provide pre-competitive access to technology, assay methodologies, high-throughput data, materials and know-how. The assays will be used for screens on publicly available small molecules at the three academic sites - Dundee, Oxford and Edinburgh - which form the National Phenotypic Screening Centre (NPSC) hubs. Industry partners gain immediate access to the developed assays to enable internal drug discovery activities, in partnership with the academic collaborators.


The PDi plans to attract additional industry partners and translate novel biology from a global network of academic collaborators. All partners will benefit from these interactions as new industry-academic partnerships are formed first-hand from novel biological research.


Prof. Andrew Hopkins


Prof.Neil Carragher


Professor Sir Peter Ratcliffe, co-founder of the PDi, who directs Oxford’s Nuffield Department of Clinical Medicine, said, “This is an exciting opportunity to bring some of the UK’s most prestigious academic institutions together with the pharmaceutical industry and change the culture in how we do translational research. We are delighted that Janssen Pharmaceutica N.V should take the lead in building this public-private partnership.“


Edinburgh University’s Professor Neil Carragher, Chief Scientific Officer for the PDi, said “The focus of the PDi consortium will be the development of novel phenotypic assays amenable to high throughput screening, with the goal of identifying new pathways and mechanisms for drug


Prof. Sir Peter Ratcliffe


discovery, by employing systems with higher potential for translation into the clinic. The phenotypic screens we will use are more relevant to patients and their disorders.”


The University of Dundee’s Professor Andrew Hopkins, PDi Chairman and co-founder, said, “All the partners involved in the PDi have a strong commitment to improving how we do drug discovery. Our recent investment of £8 million ($12 million) to build state-of-the-art screening facilities at the National Phenotypic Screening Centre provides an unparalleled platform for the PDi to achieve its mission.”


37591pr@reply-direct.com


TO BE INCLUDED IN OUR NEXT ISSUE, SEND ALL YOUR RESEARCH AND EVENTS NEWS STORIES TO HEATHER@INTLABMATE.COM


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84